The first-in-human trial of NTX1088, a monoclonal antibody, will test its activity in patients who miss out on anti-PD-1 immunotherapy benefit.
Researchers homed in on a composite biomarker to assess overall survival for HER2-positive breast cancer patients with residual disease after neoadjuvant therapy.
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
Investigators in Shanghai saw a 99 percent complete response rate among advanced B-ALL patients receiving two populations of autologous CAR T cells at once.
The growth in Lumakras sales reflect continued uptake for the KRAS G12C inhibitor in markets around the world.
The CRO has acquired a suite of assets from PACT Pharma that it hopes will bolster its product characterization services for pharma partners developing cell and gene therapies.
The firm's major growth drivers were its autologous CAR T-cell therapies Yescarta and Tecartus, as well as its antibody-drug conjugate Trodelvy.
The blockbuster immune checkpoint inhibitor brought in $5.43 billion in the quarter, maintaining its spot as Merck's single biggest pharmaceutical growth driver.
Cerianna, a radiolabeled imaging agent that reveals ER-positive breast cancers, is FDA approved as an adjunct to biopsy, but recent guidelines say it may have additional uses in certain circumstances.
By tracking blood phosphate concentrations, doctors may be able to mitigate immune effector cell neurotoxicity syndrome, according to a newly published study.